248 Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing
Kartik Sehgal(Beth Israel Deaconess Medical Center), David A. Barbie(Dana-Farber Cancer Institute), Peter S. Hammerman(Broad Institute), Silvia Goldoni(Novartis (Switzerland)), Moataz Noureddine(Dana-Farber Cancer Institute), Maria Pinzon-Ortiz, Tetsuo Tani(Keio University), Russell W. Jenkins(Broad Institute), Carino Gurjao(Broad Institute), Marios Giannakis(Broad Institute), Tyler J. Teceno(Dana-Farber Cancer Institute), Luke J. Taus(Dana-Farber Cancer Institute), Cloud P. Paweletz(Massachusetts General Hospital), Shunsuke Kitajima(Japanese Foundation For Cancer Research), Tran C. Thai(Dana-Farber Cancer Institute), Derek Liu(Harvard–MIT Division of Health Sciences and Technology), Elena V. Ivanova(Massachusetts General Hospital), Patrick H. Lizotte(Harvard University), Jonathan M. Greene, Andrew Portell(Massachusetts General Hospital), Prafulla C. Gokhale(Harvard University), Amir Vadji(Dana-Farber Cancer Institute), Navin R. Mahadevan(Brigham and Women's Hospital), David Liu(University of Louisville), William D. Hastings(Brigham and Women's Hospital), Juan J. Miret(Dana-Farber Cancer Institute), Paul Kirschmeier(Dana-Farber Cancer Institute), Christie J. Lau(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k